Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA799 | CA9581 | U.S. | 1999 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 261 |
| 2 | DDI | 65 |
| 3 | AZT+DDI | 52 |
| 4 | 3TC+AZT | 48 |
| 5 | D4T+DDC+RTV | 31 |
| 6 | D4T+DDC+IDV | 13 |
| 7 | 3TC+AZT+RTV+SQV | 13 |
| 8 | D4T+NFV+NVP | 9 |
| 9 | 3TC+AZT+D4T+IDV | 14 |
| 10 | 3TC+AZT+DDI+RTV+SQV | 27 |
| 11 | 3TC+AZT+IDV+RTV | 8 |
| 12 | 3TC+ABC+AZT+Unknown | 36 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| I54V, V82A, L90M | G73S | L10I, I15V, K20M, E35D, M36I, R57K, I62V, L63P, A71V |
| >CA9581| codons 1-99 PQITLWQRPIVTIKVGGQLMEALLDTGADDTVLEDINLPGRWKPKMIGGIGGFVKVKQYD QVPIEICGHKVISTVLVGPTPANIIGRNLMTQIGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, V75M, M184V, L210W, T215Y | D67E, K219N | K103N, Y181C | A98G | V35M, K43KQ, E44D, S68G, K122E, I135T, D177E, V179I, G196E, E203K, Q207E, V245M, A272P, V276I | N265NT |
| >CA9230| codons 1-278 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTELEQDGKISKIGPENPYNTPV FAIKKKEGTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIII CQYVDDLYVGSDLEIEQHRTKIKELREHLWRWGFYTPDNKHQKEPPFLWMGYELHPDKWT VQPIMLPEKDSWTVNDIQKLVGKLTWASQIYPGIKIKQ |
References
| Author | Title | Citation |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |